Peiqing Luo,Xiaocui Huang,Fang Luo,Zhonghui Chen,Yu Chen,Cuiying Lin,Jian Wang,Bin Qiu,Zhenyu Lin
Abstract:In this work, combined with the high amplification efficiency of hybridization chain reaction (HCR), high specificity of the CRISPR/Cas12a system, and convenience of the homogeneous electrochemiluminescence (ECL) assay based on the regulation of negative charge on the reporting probes, a sensitive ECL biosensor for hepatitis B virus DNA (chosen as a model target) had been developed. The initiator chain trigger DNA that can induce HCR amplification is modified on the surface of ruthenium...
What problem does this paper attempt to address?
### Problems Addressed by the Paper
This paper aims to develop a low-background signal turn-on homogeneous electrochemiluminescence (ECL) biosensor for the detection of Hepatitis B Virus (HBV). Specifically, the paper combines the high amplification capability of hybridization chain reaction (HCR), the high specificity of the CRISPR/Cas12a system, and the advantages of a homogeneous ECL detection method based on nanoparticle surface charge regulation to achieve high sensitivity and high accuracy detection of HBV DNA.
### Main Issues and Solutions
1. **Improving Detection Sensitivity**:
- **Problem**: Existing nucleic acid detection methods lack sensitivity when detecting low concentrations of the target, leading to potential misdiagnosis.
- **Solution**: The dual signal amplification by the CRISPR/Cas12a system and HCR technology significantly enhances the sensor's sensitivity. The sensor exhibits a strong linear relationship with the logarithm of the target concentration in the range of 10 fM to 10 nM, with a detection limit of 7.41 fM.
2. **Reducing Background Signal**:
- **Problem**: Traditional ECL biosensors have high background signals, affecting the accuracy of detection results.
- **Solution**: By adjusting the length of the DNA on the nanoparticle surface, the electrostatic interaction between the luminophore and the negative electrode is controlled, thereby reducing the background signal. Long-chain DNA prevents co-reactants from entering the pores to react with ruthenium bipyridine and enhances electrostatic repulsion, making it difficult for the luminophore to approach the electrode surface, further reducing the background signal.
3. **Improving Detection Repeatability and Stability**:
- **Problem**: Traditional electrode modification methods are complex, leading to poor repeatability and stability.
- **Solution**: This sensor does not require complex electrode modification, thus offering better repeatability and stability. Experimental results show that the sensor exhibits a good linear relationship and repeatability in detecting different concentrations of HBV DNA.
4. **Rapid Detection**:
- **Problem**: Traditional PCR technology requires thermal cycling equipment, resulting in long detection times, making rapid detection difficult.
- **Solution**: Utilizing the high-efficiency DNA cleavage characteristic of the CRISPR/Cas12a system at room temperature, combined with HCR technology, rapid signal amplification is achieved, thereby shortening the detection time.
### Experimental Validation
- **Feasibility Verification**: The feasibility of the HCR amplification reaction was verified by polyacrylamide gel electrophoresis (PAGE), and the sensor's response was verified by changes in the ECL signal.
- **Optimization Conditions**: The concentrations of trigger DNA, CRISPR/Cas12a, H1/H2 hairpin DNA, as well as the enzyme digestion time and HCR amplification time, were optimized to ensure the best detection performance.
- **Practical Application**: Tests were conducted on clinical samples, and the results showed that the sensor has high accuracy and reliability in detecting HBV DNA concentrations, consistent with clinical detection results.
### Conclusion
This study successfully constructed a homogeneous ECL biosensor based on CRISPR/Cas12a and HCR technology for the detection of HBV. The sensor has high selectivity, low detection limit, and good linear relationship, making it suitable for quantitative analysis in clinical detection. This method combines the high specificity of CRISPR/Cas12a, the high amplification capability of HCR, and the simplicity, stability, and rapid detection advantages of the homogeneous ECL system, demonstrating its potential application prospects in the field of disease detection.